66 results about "Schizophrenic disorders" patented technology

The present invention relates to a new use of phosphodiesterase 1 (PDE1) inhibitors for the treatment of psychosis, schizophrenia, schizoaffective disorder, schizophreniform disorder, psychotic disorder, delusional disorder, mania, or bipolar disorder.

The disclosure provides the use of particular substituted heterocycle fused gamma-carboline compounds as pharmaceuticals for the treatment of residual symptoms of psychosis or schizophrenia. The disclosure also provides novel long acting injectable formulations of particular substituted heterocycle fused gamma-carboline compounds and use of such long acting injectable formulations for the treatment of residual symptoms of psychosis or schizophrenia.

Solid, pharmaceutical dosage forms of [2-(8,9-dioxo-2,6-diazabicyclo [5.2.0]non-1(7)-en-2-yl)alkyl]phosphonic acid and derivatives thereof are disclosed. In addition, methods of use are disclosed for the treatment, inter alia, of cerebral vascular disorders, anxiety disorders; mood disorders; schizophrenia; schizophreniform disorder; schizoaffective disorder; cognitive impairment; chronic neurodegenerative disorders; inflammatory diseases; fibromyalgia; complications from herpes zoster; prevention of tolerance to opiate analgesia; withdrawal symptoms from addictive drugs; and pain.

Provided herein are methods for treating schizophrenia or schizoaffective disorder by administering to a subject in need thereof (S)-2-amino-3-methyl-butyric acid (2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-yl ester, or an isotopic variant thereof, or a pharmaceutically acceptable salt or polymorph thereof.

Compositions may include a pharmaceutical active agent, a high viscosity liquid carrier material (HVLCM), a lactic acid-based polymer, and an organic solvent. Related compositions and methods are also disclosed. For instance, a carrier formulation for controlled release of injectable drugs is disclosed. The formulation may include a non-water soluble high viscosity liquid which may be sucrose acetate isobutyrate, a lactic-acid based polymer which may be a poly(lactic acid)(glycolic acid), and an organic solvent which maintains the composition in a monophasic form at 25° C. in one atmosphere. Drug in the formulation may be released upon administration such that less than 10% (e.g. 2-8%) of drug is released in the first 5 hours; 10% to 80% of the drug is released during a period of 5 hours to 7 days after administration; and 10% to 40% of the drug is released gradually over a period of 7 days to 28 days from initial administration. The drug may be an anti-schizophrenia agent delivered by injection.

Novel compounds of the structural formula (I) are antagonists and / or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.

Provided are a histamine-H3 receptor antagonist; and a preventive and / or a remedy for metabolic system diseases such as obesity, diabetes, hormone secretion disorder, hyperlipemia, gout, fatty liver, circulatory system diseases, for example, stenocardia, acute / congestive cardiac insufficiency, cardiac infarction, coronary arteriosclerosis, hypertension, nephropathy, sleep disorder and various diseases accompanied by sleep disorder such as idiopathic hypersomnia, repetitive hypersomnia, true hypersomnia, narcolepsy, sleep periodic acromotion disorder, sleep apnea syndrome, circadian rhythm disorder, chronic fatigue syndrome, REM sleep disorder, senile insomnia, night worker sleep insanitation, idiopathic insomnia, repetitive insomnia, true insomnia, electrolyte metabolism disorder, and central and peripheral nervous system diseases such as bulimia, emotional disorder, melancholia, anxiety, epilepsy, delirium, dementia, shinzophrenia, attention deficit / hyperactivity disorder, memory disorder, Alzheimer's disease, Parkinson's disease, sleep disorder, recognition disorder, motion disorder, paresthesia, dysosmia, epilepsy, morphine resistance, narcotic dependency, alcoholic dependency. The histamine-H3 receptor antagonist comprises a piperidine derivative compound of formula (I) [wherein X1 and X2 independently represent a nitrogen atom or CH; Y represents a specific group; X3 represents Os—(CH2)m; R1 and R2 independently represent a hydrogen atom, a halogen atom, a linear or branched lower alkyl group, a lower alkoxy group, or an acetyl group substituted with 2 or 3 fluorine atoms; s is 0 or 1; and m is an integer to make (m+s) 0 or from 1 to 4], or its pharmaceutically-acceptable salt.

5- and 6-membered heterocyclic compounds which are inhibitors of phosphodiesterase 10 are described as are processes, pharmaceutical compositions, pharmaceutical preparations and pharmaceutical use of the compounds in the treatment of mammals, including human(s) for central nervous system (CNS) disorders and other disorders which may affect CNS function. Also described is the treatment of neurological, neurodegenerative and psychiatric disorders including but not limited to those comprising cognitive deficits or schizophrenic symptoms.

The invention relates to a penfluridol oral preparation with novel specifications. Each dosage unit contains 2.5 to 3 mg of penfluridol. When the medicament of the invention is used, the prior common method of taking 20 mg of the medicament is changed from once a week into once a day. The oral preparation is used for the maintenance treatment of schizophrenics after undergoing other psychotherapy and pharmacotherapy and having obviously relieved symptoms, prevents relapse, avoids the side effects of taking the medicament once a week, and is economical, effective and fewer in side effects than other maintaining medicaments.

Embodiments of the present invention provide methods for diagnosing schizophrenia, schizo-affective disorder and / or psychosis in an individual or predicting risk of the individual developing schizophrenia, schizo-affective disorder or psychosis, by determining values for one or more markers in each of five domains, namely a neurotransmitter domain, an oxidative stress domain, a nutrition-biochemistry domain, a visual processing domain and an auditory processing domain.

The invention belongs to the field of psychiatry, nerve images and artificial intelligence, discloses a construction method of a first episode schizophrenia individualized prediction model, and solvesthe problem of low accuracy of auxiliary diagnosis of an existing SCH brain structure network model. The method comprises the following steps: A, acquiring a diffusion tensor image of a first episodeschizophrenia patient; B, preprocessing the obtained diffusion tensor image; C, constructing a sparse brain structure network based on the preprocessed image; D, constructing each sparse multi-threshold fusion brain structure network of the subject by adopting a similar network fusion method; E, extracting multi-threshold fusion brain structure network topology attribute features, and then carrying out feature screening; F, based on the screened features, adopting a classifier for classification training, and obtaining a first episode schizophrenia individualized prediction model is obtained;and G, performing performance verification and evaluation on the first episode schizophrenia individualized prediction model obtained by training.

This invention relates to methods and compositions for diagnosing and treating neuropsychiatric disorders, such as schizophrenia, schizoaffective disorder, bipolar affective disorder, unipolar affective disorder and adolescent conduct disorder. In particular, the invention provides novel variants of DISC1 and DISC2 nucleic acid sequences, as well as novel DISC1 polypeptides encoded by these variant nucleic acid sequences. The variant DISC1 and DISC2 nucleic acid sequences provided by this invention, and the variant gene products they encode, are ones that correlate with the presence of a neuropsychiatric disorder in individuals. The invention, therefore, also provides methods and compositions for using the variant nucleic acids and polypeptides to diagnose and treat such neuropsychiatric disorders in individuals.

The present invention relates of the mammalian HKNG1 gene, a gene associated with bipolar affective disorder (BAD) in humans. The invention relates, in particular, to methods for the diagnostic evaluation, genetic testing and prognosis of HKNG1 neuropsychiatric disorders including schizophrenia, attention deficit disorder, a schizoaffective disorder, a bipolar affective disorder or a unipolar affective disorder.

The present invention relates to the use of sertindole in the preparation of a pharmaceutical composition for the preventive treatment of suicidal behaviour in human subjects suffering from a psychotic illness such as schizophrenia or schizoaffective psychosis.

One aspect of the present invention relates to heterocyclic compounds. A second aspect of the present invention relates to the use of the heterocyclic compounds as ligands for various mammalian cellular receptors, including dopamine transporters. The compounds of the present invention will find use in the treatment of numerous ailments, conditions and diseases which afflict mammals, including but not limited to addiction, anxiety, depression, sexual dysfunction, hypertension, migraine, Alzheimer's disease, obesity, emesis, psychosis, analgesia, schizophrenia, Parkinson's disease, restless leg syndrome, sleeping disorders, attention deficit hyperactivity disorder, irritable bowel syndrome, premature ejaculation, menstrual dysphoria syndrome, urinary incontinence, inflammatory pain, neuropathic pain, Lesche-Nyhane disease, Wilson's disease, and Tourette's syndrome. An additional aspect of the present invention relates to the synthesis of combinatorial libraries of the heterocyclic compounds, and the screening of those libraries for biological activity, e.g., in assays based on dopamine transporters.

Isoquinolone derivatives of the general formula I are provided. The compounds are NK3 antagonists and useful for the treatment of e.g. psychosis and schizophrenia.

A predictor of the period of psychotic episode in individual schizophrenia patients, and its method. It consists of, a data constructor and an incident simulator, which concludes rules from the total incidents of patients' recurrence as well as the historical time data. Then it applies the said rules to predict the following happening time of a recurrence or a stabled situation.

Disclosed is a medicinal composition for treating schizophrenosis which is prepared from plaster stone, rhubarb horsetails, baikal skullcap root, corktree bark, celestite, goldthread root, curcuma aromatica, mirabilite, keel, hooked uncaria, cow-bezoar, mirabilite, natural indigo, grassleaved sweetflag rhizome, mentha, magnolia bark, aloe, bamboo leaves, spatholobus stem, boneol, magnolia bark, aloe, Chinese angelica root, banksia rose, rough gentian, immature bitter orange, green tangerine orange peel and riddle.

The invention belongs to the technical field of drug eutectics, and particularly relates to two novel paliperidone drug eutectics and a preparation method of the novel paliperidone drug eutectics, wherein one paliperidone molecule and one p-hydroxybenzoic acid molecule are combined together by a hydrogen bond to form the basic structure unit of a paliperidone drug eutectic CC-1; and two paliperidone molecules are respectively combined with one p-hydroxybenzoic acid molecule by a hydrogen bond to form the basic structure unit of a paliperidone drug eutectic CC-2. The preparation method of the paliperidone drug eutectics CC-1 and CC-2 is a solvent room-temperature volatilization method. The prepared paliperidone drug eutectics in the invention inherits the characteristic of the traditional bulk drug in treating dementia praecox, in addition, the dissolubility, the stability and the bioavailability of the prepared paliperidone drug eutectics are improved obviously.

The present invention provides a method for identifying compounds which modulate the interaction of Nogo and Nogo receptor (NgR). The present invention also provides compounds that modulate the interaction of Nogo and Nogo receptor (NgR), the use of such compounds and compositions in the treatment or amelioration of conditions diseases or disorders, such as spinal cord injury, traumatic brain injury, stroke, multiple sclerosis, ALS, Huntington's disease, Alzheimer's disease, Parkinson's disease, epilepsy, Schizophrenia or schizoaffective disorders.

The invention relates to a method for preparing lurasidone and a salt thereof. The method comprises the following steps: reacting (R,R)-1,2-bis(methanesulfonyloxymethyl)cyclohexane and 3-(1-piperazinyl)-1,2-benzoisothiazole hydrochloride in acetonitrile in the presence of potassium carbonate to obtain an intermediate I; reacting the intermediate I with (3aR,4S,7R,7aS)-4,7-methylene-1H-isoindole-1,3(2H)-dione in DMF in the presence of potassium carbonate to prepare lurasidone free alkali; and reacting the lurasidone free alkali with hydrochloric acid in isopropanol to obtain lurasidone hydrochloride. The invention also relates to lurasidone and the salt thereof prepared by using the method, and application of lurasidone and the salt thereof in medicines for resisting psychosis, especially schizophrenia. The method disclosed by the invention has one or more advantages in a group consisting of simple process, high product yield, few impurities and the like.

The invention discloses a medicament for treating schizophrenia and a preparation method thereof. The medicament for treating the schizophrenia is prepared from the following main raw materials in parts by weight: 25-45 parts of lily, 8-16 parts of rhizoma cyperi, 6-12 parts of erctmochelys imbricata, 10-16 parts of radix paeoniae alba, 9-12 parts of poria with hostwood, 6-15 parts of polygala tenuifolia, 3-9 parts of polygonum multiflorum, 10-16 parts of Chinese herring, 6-9 parts of semen cuscutae, 5-15 parts of calamus, 6-12 parts of schisandra chinensis, 4-10 parts of mulberry leaf, 9-16 parts of blackend swallowwort root, 6-15 parts of tangerine leaf, 5-12 parts of rehmannia root, 9-18 parts of medicinal cyathula root, 6-10 parts of scrophularia ningpoensis, 12-20 parts of lotus leaf, 5-10 parts of hericium erinaceus, 8-12 parts of dried tangerine or orange peel, 3-6 parts of dens draconis and 5-9 parts of radix ophiopogonis. The medicament for treating the schizophrenia has quick effect, obvious curative effect and no toxic and side effect.

The present invention concerns substituted pyrazinone derivatives according to the general Formula (I) a pharmaceutically acceptable acid or base addition salt thereof, a stereo- chemically isomeric form thereof, an N-oxide form thereof or a quaternary ammonium salt thereof, wherein the variables are defined in Claim 1, having se- lective a2C-adrenoceptor antagonist activity. It further relates to their preparation, compositions comprising them and their use as a medicine. The compounds according to the invention are usefull for the prevention and / or treatment of central nervous system disorders, mood disorders, anxiety disorders, stress-related disorders associated with depression and / or anxiety, cognitive disorders, personality disorders, schizoaffective disorders, Parkinson's disease, dementia of the Alzheimer's type, chronic pain conditions, neurodegenerative diseases, addiction disorders, mood disorders and sexual dysfunction.

The invention belongs to the technical field of biomedicine and particularly relates to a novel pharmaceutical use of a dopamine receptor 1 antagonist, and to a novel use of the dopamine receptor 1 antagonist in preparing drugs for the treatment of ketamine-induced schizoid symptoms in mice. The dopamine receptor 1 antagonist is selected from SCH23390 having a molecular formula of C17H18ClNO.HCl,and is one or only one effective ingredient to the drugs. A drug for the treatment of ketamine-induced schizoid symptoms in mice comprises the dopamine receptor 1 antagonist having the effective amount (5 mg / kg). The dopamine receptor 1 antagonist is used as one means to treat ketamine-induced schizoid behaviors of mice, and scientific basis is provided for the research and development of a methodto effectively relieve schizoid symptoms in mice.

The invention relates to a traditional Chinese medicine composition, a preparation method and an application thereof, and a preparation containing the composition, which belong to the technical field of traditional Chinese medicine pharmacy. The traditional Chinese medicine composition contains the following raw material medicines in parts by weight: 8-15 parts of rhizoma atractylodis, 10-20 parts of areca-nut, 8-15 parts of mangnolia officinalis, 8-15 parts of fruit of immature citron, 8-12 parts of rhizoma acori graminei, 8-15 parts of platycodon grandiflorum, 8-15 parts of common hogfennel root, 8-15 parts of tuckahoe, 8-12 parts of fructus perillae and 8-12 parts of fritillaria, and the traditional Chinese medicine composition is used for treating such symptoms caused by overnutrition, non-scientific feeding and a variety of complicated social and ecological factors as hyperglycemia, hypertension, hyperlipidemia, fatty liver, overweight, constipation, loose stool, abdominal distension, gastrointestinal disorder, insomnia, palpitation, myocardial infarction, cerebral apoplexy, backache and leg pain, amnesia, schizophrenia, impotence, irregular menstruation, infertility and even cancers, and the traditional Chinese medicine composition has the advantages of good curative effect, quick effect, wide disease treatment spectrum, non-toxic side effect, low treatment cost, no rare medicinal herb, simple preparation method, etc.

Provided herein are methods for diagnosing a psychotic disorder, such as schizophrenia, schizoaffective disorder or psychosis, predicated on a determination of a methylation phenotype of the subject based in part on the identity of a specific polymorphism in the MTHFR gene and the analysis of a suite of biomarkers and other functional measures and indices. Also provided herein are methods for predicting prognosis and functional outcomes for subjects having a psychotic disorder, and for treating subjects having a psychotic disorder.

The invention discloses pills (capsules) for awakening brain and resuscitation and relates to the pharmaceutical field, the drug composition can cure schizophrenia in a short period of time and has the effects of tranquillization, nourishing heart, clearing fire, eliminating sputum, regulating qi, relieving qi stagnation, opening orifice, resuscitation and awakening brain for internal injuries caused by seven emotions of joy, anger, worry, miss, sorrow, fear and surprise and the schizophrenia caused by fire, stagnation and sputum obstruction, thereby achieving the special effects of recovering spirit and curing without recurrence. The main pharmaceutical ingredients comprise 10g of bezoar, 10g of amber, 10g of cinnabar, 3g of musk, 10g of vermiculite schist seu, 20g of stir-fried spina date seed, 20g of thinleaf milkwort root-bark, 10g of drug sweetflag rhizome, 10g of golden thread, 10g of turmeric root-tuber, 10g of dwarf lilyturf tuber and 6g of liquoric root, the pharmaceutical ingredients are ground together into fine flour and filled in capsules for oral administration, the dosage is 10 capsules a time and three times a day, and the capsules have no side effects.

The invention provides a schizophrenia classifying method based on task switch test behavior data, in order to solve the problems that the present schizophrenic characteristic data acquisition is highin cost, the analysis is complex, the quick, objective and accurate response cannot be made, and the like. The method comprises the following steps: establishing a task switch test experimental procedure; acquiring a task switch test experimental data of a tested user, namely, response time and accuracy; calculating the response time difference related to the execution control according to average response time; utilizing the task switch test experimental data and the response time difference related to the execution control as features for training the optimal self-adaption promotion classifier; using a cross validation method for verifying the optimal self-adaption promotion classifier. According to the schizophrenia classifying method, 90% of classification accuracy, 100% of sensitivity and 81% of specificity can be achieved; the area under the working characteristic curve of the tested user is 0.89; the method is capable of providing objective and effective assistance in identifying the schizophrenic patient and has a huge potential application value in the research field of mental diseases.

Compositions and methods relating to the diagnosis and treatment of neuropsychiatric disorders, such as schizophrenia, schizoaffective disorders, and bipolar disorders are disclosed. Also provided are methods for screening therapeutic agents having efficacy for the treatment of such disorders.